Market capitalization | $47.98m |
Enterprise Value | $-35.41m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.34 |
P/B ratio (TTM) P/B ratio | 0.57 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-187.55m |
Free Cash Flow (TTM) Free Cash Flow | $-103.33m |
Cash position | $123.12m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
7 Analysts have issued a Allakos, Inc. forecast:
7 Analysts have issued a Allakos, Inc. forecast:
Dec '23 | |
Current assets | 180 180 |
Fixed assets | 64 64 |
Total Assets | 244 244 |
Dec '23 | |
Equity | 169 169 |
Debt capital | 75 75 |
Total Capital | 244 244 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
Head office | United States |
CEO | Robert Alexander |
Employees | 131 |
Founded | 2012 |
Website | www.allakos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.